Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT NHL Vaccine
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
**NANT NHL Vaccine** is an investigational, sponsor-specific multimodal cancer-immunotherapy regimen evaluated as QUILT-3.052 for relapsed CD20-positive non-Hodgkin lymphoma after rituximab therapy. Rather than a single molecular vaccine, it is a protocol-level combination that can incorporate metronomic chemotherapy, tumor-antigen vaccination, immune-cell therapy, cytokine stimulation, targeted antibodies, and radiotherapy. The registered study was a Phase 1b/2 trial and is listed as withdrawn; therefore, this program should not be treated as an approved or currently established lymphoma vaccine. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03169790))
- Other names
- NANT Non-Hodgkin Lymphoma Vaccine
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on NANT NHL Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT NHL Vaccine.